Over the past 30 years, the pharmaceutical industry has substantively redesigned every part of the bioproduction process, considerably improving productivity. However, in this time the CHO cell itself, arguably the greatest potential source of efficiency improvements, has remained largely unchanged.
The CHO genome was first sequenced in 2011; however, the current annotation is not suitable for whole-genome screening. Together with licensing terms that restrict modification of the cells, this has meant progress in cell-line improvement has been slow.
This has been a source of considerable frustration among drug manufacturers, as there has been increasing interest in improving productivity through cell-line innovation since the emergence of gene-editing tools such as CRISPR.
To address this problem, Horizon and its partners — the Wellcome Trust Sanger Institute and Eagle Genomics — have established a high-quality sequence map based on Horizon’s GS Knock-Out CHO K1 cell line.
Abel Ureta-Vidal, CEO of Eagle Genomics, said: “Genome assembly and annotation are essential to genomic data innovation and to drive product development. Unfortunately, generating a CHO reference genome of sufficient quality for applications like genome engineering has been notoriously difficult due to aneuploidy and complex chromosome rearrangements of the cell line.
"It is gratifying that now, for the first time, a commercially available bioproduction cell line can be directly paired with its detailed reference genome and we believe this will be vital to unlocking the potential of the cell lines.”
By releasing this sequence into the public domain, Horizon hopes to enable genuine quality-by-design in bioproduction cell-line development, through the widespread ability to identify genes that, if modified, could improve the phenotype of interest.
Dr Thomas Keane, who led the sequencing team at the Wellcome Trust Sanger Institute, said: “We are committed to scientific openness and data sharing and are very pleased to have produced the high resolution sequencing foundation for the public release of the CHO sequence data.
This openness is an important aspect for us of our collaboration with Horizon, as the availability of the data will enable further research and development in the scientific community.
Horizon’s GS Knock-Out CHO K1 cell line was chosen as the basis for this project as it is manufacturing ready and licenses come with the right to modify the cells, which is highly unusual among commercially available GS CHO KO cells. The use of Horizon’s cells alongside the public sequence thereby provides the ideal base and dataset to enable screening providing immediately actionable results.
The public sequence can also be applied to any other CHO cell line; but, additional validation of sequence may be required to confirm the cell line being used does not differ in any meaningful way from the public sequence.
Dr Darrin M Disley, CEO of Horizon Discovery Group, said: “Horizon’s open philosophy on sequence data, alongside our disruptive cell line licensing model, continues to challenge the industry and push the boundaries in bioproduction.
"It is our belief that greater innovation in the bioproduction space ultimately benefits the patient through enabling the commercial manufacture of therapeutics that would not be possible with existing solutions. Eagle Genomics has proven the ideal partner for this project, and we look forward to collaborating with them on similar ventures in the future.”
